BioClever 2005 S.L.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Barcelona Spain (2009)

Organization Overview

First Clinical Trial
2019
NCT03799744
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

BioClever 2005 S.L.

Active Ingredients

Drugs in Phase 3 Trials (3)

alk alutard 5-grasses (1 trial)

bactek-r (1 trial)

house dust mite allergen (1 trial)

Drugs in Phase 2 Trials (1)

glucarpidase (voraxaze) (1 trial)

Drugs in Phase 1 Trials (2)

durvalumab (imfinzi) (1 trial)

vcn-01 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 1)

Carcinoma, Squamous Cell (Phase 1)

Head and Neck Neoplasms (Phase 1)

Pneumonia (Phase 3)

Recurrence (Phase 1)

Squamous Cell Carcinoma of Head and Neck (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 6